FTH

AI Memo

Faeth Therapeutics

As of 2026-10-15/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

PIK-201 Phase 2 endometrial-cancer topline data • 2026-12-31

Base target: $18 / p=40% prob

Biggest risk

An inconclusive or poorly tolerated PIK-201 result would undermine the lead program. Q2 R&D expense rose to $9.2 million from $2.5 million a year earlier as PIKTOR trial, manufacturing and personnel costs increased. [#SEC-8K-2026-08-04]

Invalidation

Break below $7 or thesis failure.

What would change my mind?

Positive PIK-201 data could validate Faeth's multi-node approach and support further development. The company reported $186.4 million of cash, cash equivalents and marketable securities at June 30, 2026, following its financing. [#SEC-8K-2026-08-04]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-15

Base target

$18

p=40%

Bull target

$38

p=20%

Bear target

p=40%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

PIK-101 initial breast-cancer data
Positive PIK-201 data could validate Faeth's multi-node approach and support further development.
The company reported $186.4 million of cash, cash equivalents and marketable securities at June 30, 2026, following its financing.

BearKey bullets

Higher clinical-development spending could shorten the effective runway if costs rise or trials expand.
[#SEC-8K-2026-08-04]
PIK-101 is early-stage, with initial data not anticipated until 2027.

WatchKey bullets

PIK-201 Phase 2 endometrial-cancer topline data

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $18 (p=40%)

Target spread vs base: +111% / -61%

Scenario probabilities

Bull Target: $38 (p=20%)Base Target: $18 (p=40%)Bear Target: $7 (p=40%)

Commentary

Recent company news centered on the PIK-201 readout and an October 6 KOL event, not a reported Phase 2 result. A September 8 company notice continued to anticipate topline data by year-end. [#PR-2026-09-08] The September 17 8-K documented Karen Vousden's board appointment, not a clinical update. [#8-K-2026-09-17] The packet's deterministic directional prior is negative despite strong primary-source coverage. Social, options, short-interest, employee and dependable analyst-revision measures are unavailable; zeros above denote missing data, not neutral readings.

As of 2026-10-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

PIK-101 initial breast-cancer data

Scenarios

Bull Target (Scenario probability)

$38 / p=20% prob

Base Target (Scenario probability)

$18 / p=40% prob

Bear Target (Scenario probability)

$7 / p=40% prob

Analysis 2026-10-15 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
PIK-201 Phase 2 endometrial-cancer topline data
Faeth expects topline data by year-end 2026. This is the principal near-term value inflection, but clinical efficacy and tolerability remain unproven. The FDA Fast Track designation applies to PIKTOR plus paclitaxel in a specified biomarker-selected population; it is not an approval. [#SEC-8K-2026-08-04] [#PR-2026-08-17]
Prob 70.00% • Move 35.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

PIK-101 initial breast-cancer data
2027-12-31
The first patient was dosed in the Phase 1b/2 HR+/HER2- breast-cancer trial in April 2026, and Faeth anticipates initial data in 2027. This could test PIKTOR beyond endometrial cancer, but the program remains early-stage. [#SEC-8K-2026-08-04]
Prob 60% • Move 20% • Priced-in 15%

Risks

Higher clinical-development spending could shorten the effective runway if costs rise or trials expand. [#SEC-8K-2026-08-04]
PIK-101 is early-stage, with initial data not anticipated until 2027. [#SEC-8K-2026-08-04]
PIK-201 efficacy, safety and readout timing are binary risks; Fast Track designation does not establish approval or clinical success. [#PR-2026-08-17]
Sparse analyst-target metadata and loose peer comparability limit valuation confidence.

Peers

Symbol	Summary
DRUG	Similar-market-cap clinical-stage biotech reference; therapeutic focus differs, so it is a loose financing and binary-trial-risk comparison rather than a direct program peer.
PBYI	Same-sector, similar-market-cap oncology reference, but its commercial-stage profile is not a direct match for Faeth's clinical-stage, PIKTOR-dependent valuation.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-15

Loading AI feed…

Symbol

Summary

DRUG

Similar-market-cap clinical-stage biotech reference; therapeutic focus differs, so it is a loose financing and binary-trial-risk comparison rather than a direct program peer.

PBYI

Same-sector, similar-market-cap oncology reference, but its commercial-stage profile is not a direct match for Faeth's clinical-stage, PIKTOR-dependent valuation.